Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.97 USD
Change Today +0.06 / 0.87%
Volume 226.7K
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

trevena inc (TRVN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $8.16
52 Week Low
12/9/14 - $3.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TREVENA INC (TRVN)

Related News

No related news articles were found.

trevena inc (TRVN) Related Businessweek News

No Related Businessweek News Found

trevena inc (TRVN) Details

Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline includes TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its central nervous system product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment-refractory migraine headaches. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase II clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

42 Employees
Last Reported Date: 03/18/15
Founded in 2007

trevena inc (TRVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $686.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $465.3K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $469.2K
Compensation as of Fiscal Year 2014.

trevena inc (TRVN) Key Developments

Trevena, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Trevena, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $625,000. Loss from operations was $13,063,615 against $9,654,374 a year ago. Net loss attributable to common stockholders was $12,929,645 against $9,401,935 a year ago. Net loss per share of common stock, basic and diluted was $0.33 against $0.59 a year ago.

Trevena, Inc. Appoints Carrie L. Bourdow as Senior Vice President and Chief Commercial Officer

Trevena, Inc. announced the appointment of Carrie L. Bourdow as senior vice president and chief commercial officer, effective immediately. Ms. Bourdow brings over 25 years of experience in pharmaceutical sales and marketing. Most recently, she was vice president of marketing, reimbursement, and operations at Cubist Pharmaceuticals, Inc. Prior to joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc.

Trevena, Inc. Enters into First Amendment to Loan and Security Agreement

On April 13, 2015, Trevena, Inc. entered into a first amendment to the loan and security agreement dated as of September 19, 2014 with Oxford Finance LLC, as collateral agent and lender and Square 1 Bank, as lender. Under the Agreement, the Lenders agreed to lend the company up to $35.0 million in a series of term loans. Upon entering into the Agreement on September 19, 2014, the company borrowed $2.0 million from the Lenders (Term Loan A). Under the terms of the Agreement, the company may, at its sole discretion, borrow from the Lender: up to an additional $16.5 million (Term Loan B), at any time on or before June 30, 2015 since the company has satisfied specified conditions precedent related to the results of the Company's ongoing Phase 2 studies of TRV130; and an additional $16.5 million (Term Loan C), at any time on or before March 31, 2016, subject to the company's satisfaction of specified conditions precedent related to the results of the company's ongoing Phase 2 studies of TRV027, as described in the Agreement. Under the First Amendment, the period during which the company can draw Term Loan B has been modified to the period beginning on October 1, 2015 and ending on December 31, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRVN:US $6.97 USD +0.06

TRVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRVN.
View Industry Companies

Industry Analysis


Industry Average

Valuation TRVN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 434.0x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 271.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TREVENA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at